Tradestie Institutional Equity Comparison Engine · Market Close Nov 20, 2026

LYEL vs NUVB: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

LYEL Captures Overall Composite Edge (35.1 SELL vs 61.0 BUY), While NUVB Leads 4–1 on Growth & Valuation Pillars

LYEL Overall Winner 6-Pillar Tally: LYEL 1 – 4 NUVB (1 Tie) Matrix Metrics: LYEL 2 – 6 NUVB

As of Nov 20, 2026, Lyell Immunopharma, Inc. (LYEL) captures the overall head-to-head institutional edge over Nuvation Bio Inc. (NUVB) on higher Unified Composite conviction (35.1/100 SELL vs. 61.0/100 BUY) after splitting the core matrix 2–6 (led by Options & Positioning), while NUVB wins 4–1 across the 6-pillar growth and valuation breakdown. LYEL trades at $13.80 (N/M Forward P/E, -1341693.4% operating margin) versus NUVB at $3.80 (N/M Forward P/E, -61.2% operating margin).

  • Composite vs. Pillar Nuance: While NUVB currently prints a higher short-term Unified Composite Score (61.0/100 BUY vs. LYEL 35.1/100 SELL), LYEL captures the overall institutional head-to-head verdict (2–6 matrix metrics and 1–4 across the 6 pillars) due to superior fundamental profitability (-1341693.4% vs. -61.2% operating margin) and revenue trajectory (-80.0% vs. +242.6% YoY).
  • Technical & Structure Timing Caution: LYEL trades in a Neutral technical trend (SURGE options phase, RSI 55.5); meanwhile NUVB is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 31.3). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About LYEL vs NUVB
LYEL NASDAQ Head-to-Head Winner
Lyell Immunopharma, Inc. Common Stock
Pharmaceutical Preparations
$13.80
+1.62% 1D
Market Cap $434.8M
TTM Revenue $15,000
Forward P/E N/M
Beta / 30D Vol 1.62β · 163% Vol
Unified Composite Score
35.1 / 100 SELL
Tech 15.0 Fund 39.0 Flow 67.0 Mom 40.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 55
RSI-14: 55.5 · SMA20: $13.41 · SMA50: $11.08
NUVB NYSE
Nuvation Bio Inc.
Pharmaceutical Preparations
$3.80
-0.26% 1D
Market Cap $1.3B
TTM Revenue $202M
Forward P/E N/M
Beta / 30D Vol 1.52β · 55% Vol
Unified Composite Score
61.0 / 100 BUY
Tech 53.0 Fund 61.0 Flow 67.0 Mom 64.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -16.7%), weak momentum, RSI 31
RSI-14: 31.3 · SMA20: $4.28 · SMA50: $4.87

6-Pillar Scorecard Institutional Category Breakdown (LYEL 1 – 4 NUVB)

Columns: Metric · LYEL · NUVB
1. Valuation Multiples NUVB
Forward P/E N/M N/M
Trailing P/E N/M N/M
PEG Ratio N/M N/M
EV / Revenue N/M 7.4x
2. Growth & Scale NUVB
Revenue Growth (YoY) -80.0% +242.6%
Earnings Growth (YoY) +0.0% +0.0%
TTM Revenue (USD) $15,000 $202M
Market Cap $434.8M $1.3B
3. Profitability & Quality NUVB
Gross Margin 100.0% 85.8%
Operating Margin -1341693.4% -61.2%
Net Profit Margin 0.0% -67.4%
Return on Equity (ROE) -97.8% -49.1%
4. Balance Sheet & Cash Flow NUVB
Cash Generation (TTM) -$140M -$108M
Cash Flow Margin N/A -53.6%
Net Cash / Leverage $58M Net Cash $146M Net Debt (1.32x D/E)
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning LYEL
Options Structure Phase SURGE BREAKDOWN
Current IV / %ile 258.5% (58th %ile) 65.2% (26th %ile)
Put/Call OI Skew N/A 0.24x (Call-Skewed)
OBV Trend / Tech Phase NEUTRAL · Neutral DISTRIBUTION · Markdown
6. R&D & Supply-Chain Moat Tie
OpEx & R&D Intensity N/A N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Biotechnology Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: LYEL (2) vs NUVB (6)
Institutional Metric LYEL NUVB Criterion Row Edge
Market Capitalization
Scale
$434.8M $1.3B Larger Scale NUVB
Trailing P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Forward P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Revenue Growth (YoY)
Growth
-80.0% +242.6% Higher Growth NUVB
Operating Margin (TTM)
Profitability
-1341693.4% -61.2% Higher Margin NUVB
Net Profit Margin
Profitability
0.0% -67.4% Higher Margin LYEL
Return on Equity (ROE)
Capital Efficiency
-97.8% -49.1% Higher ROE NUVB
52-Week Range Position
Momentum
18% ($7–$45) 2% ($4–$10) Stronger Trend LYEL
Beta / 30D Volatility
Risk Regime
1.62β · 163% Vol 1.52β · 55% Vol Lower Realized Risk NUVB
Unified Institutional Score
Composite Signal
35.1 / 100 (SELL) 61.0 / 100 (BUY) Higher Composite NUVB
Trailing 12M Revenue (USD)
Operating Scale
$15,000 $202M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
100.0% 85.8% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · N/M EV/Rev N/M PEG · 7.4x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$140M ($58M Net Cash) -$108M ($146M Net Debt (1.32x D/E)) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon LYEL +66.27 pp
LYEL: +47.12% · NUVB: -19.15%
3M Horizon LYEL +37.41 pp
LYEL: -6.38% · NUVB: -43.79%
6M Horizon NUVB +1.47 pp
LYEL: -20.96% · NUVB: -19.49%
1Y Horizon LYEL +26.99 pp
LYEL: -19.86% · NUVB: -46.85%

Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant USD Revenue & Operating Margin (%)
Period LYEL Revenue NUVB Revenue LYEL Op. Margin NUVB Op. Margin Margin Leader
FY2019 $0M N/A -15538.7% N/A LYEL
FY2020 $10M N/A -2732.6% N/A LYEL
FY2021 $10M N/A -2016.7% N/A LYEL
FY2022 $80M N/A -220.9% N/A LYEL
FY2023 $0M N/A -190006.2% N/A LYEL
FY2024 $0M $10M -588123.0% -7527.3% NUVB
FY2025 $0M $60M -748344.4% -338.7% NUVB

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
LYEL SURGE
7d in phase · OBV NEUTRAL
Current IV 258.5%
IV Percentile 58th %ile
Put/Call OI Skew N/A
IV Regime Balanced (25th–60th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow NEUTRAL
Exact LYEL Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
NUVB BREAKDOWN
105d in phase · OBV DISTRIBUTION
Current IV 65.2%
IV Percentile 26th %ile
Put/Call OI Skew 0.24x (Call-Skewed)
IV Regime Balanced (25th–60th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow DISTRIBUTION
Exact NUVB Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
LYEL Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $434.8M market capitalization and -1341693.4% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
NUVB Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $1.3B market capitalization and -61.2% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ LYEL vs NUVB Key Questions & Quantitative Answers

As of Nov 20, 2026, Lyell Immunopharma, Inc. (LYEL) captures the overall head-to-head institutional edge over Nuvation Bio Inc. (NUVB) on higher Unified Composite conviction (35.1/100 SELL vs. 61.0/100 BUY) after splitting the core matrix 2–6 (led by Options & Positioning), while NUVB wins 4–1 across the 6-pillar growth and valuation breakdown. LYEL trades at $13.80 (N/M Forward P/E, -1341693.4% operating margin) versus NUVB at $3.80 (N/M Forward P/E, -61.2% operating margin). Composite vs. Pillar Nuance: While NUVB currently prints a higher short-term Unified Composite Score (61.0/100 BUY vs. LYEL 35.1/100 SELL), LYEL captures the overall institutional head-to-head verdict (2–6 matrix metrics and 1–4 across the 6 pillars) due to superior fundamental profitability (-1341693.4% vs. -61.2% operating margin) and revenue trajectory (-80.0% vs. +242.6% YoY). Technical & Structure Timing Caution: LYEL trades in a Neutral technical trend (SURGE options phase, RSI 55.5); meanwhile NUVB is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 31.3). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

NUVB leads the Growth & Scale pillar: LYEL posts -80.0% YoY revenue growth and +0.0% YoY earnings growth on $15,000 TTM revenue (100.0% gross margin, -1341693.4% operating margin), compared with NUVB at +242.6% YoY revenue growth and +0.0% YoY earnings growth on $202M TTM revenue (85.8% gross margin, -61.2% operating margin). Across the 7-period historical trajectory (FY2019 to FY2025), LYEL cumulative revenue shifted +700.0% while NUVB shifted +500.0%. In operating R&D and SG&A reinvestment, LYEL deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for NUVB.

NUVB screens cheaper on headline valuation multiples. LYEL trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported FCF margin), whereas NUVB trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 7.4x EV/Revenue (-53.6% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against LYEL (-97.8% ROE) versus NUVB (-49.1% ROE) capital efficiency.

In options market volatility and institutional positioning, LYEL carries 258.5% implied volatility (58th %ile, Balanced (25th–60th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in a SURGE options structure phase (1.62β · 163% Vol realized risk). By comparison, NUVB carries 65.2% implied volatility (26th %ile, Balanced (25th–60th %ile)), a 0.24x (Call-Skewed) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a BREAKDOWN options structure phase (1.52β · 55% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 20, 2026. For educational research only; not investment advice.